Health Moderna and Merck report 42% lower melanoma recurrence risk with personalized mRNA vaccine Moderna and Merck personalized mRNA vaccine cut melanoma recurrence or death risk by 42% in Phase 3 trial with Keytruda;... CyberOGZ Team Oct 24, 2026 7 views
